Observational studyBMJ health & care informatics2025
Allergy alerting and overrides for opioid analogues across two health systems.
Observational study in BMJ health & care informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesDespite opioids comprising a majority of drug allergy alert (DAA) overrides, few studies have designed recommendations for clinical decision support (CDS) systems. We determined the frequency of opioid analogue DAA overrides and assessed DAAs overridden by patient and provider type, the most common allergic reactions documented in electronic health records (EHR), reaction severity, and associated hypersensitivity.
methodsWe conducted an observational cross-sectional study of DAAs in two geographically remote health systems. Patients were included if they were 18 years or older and had an opioid DAA generated when a medication was ordered. Patient and provider demographics, drug allergies, medication ordered, alert overrides, drug allergy reactions and DAA history were collected. Opioid analogue allergies were analysed by reaction type documented in the EHR, reaction severities (high, medium or low) and hypersensitivity reaction. Based on these factors, alerts were recommended to be interruptive requiring a coded response or changed to be non-interruptive (informational).
resultsThere were 700 493 alerts concerning opioid analogues fired for 50 527 patients across both sites, and 71.8% of these alerts were overridden. Nearly three-quarters of overridden reactions had a low to medium severity level at both institutions. Only 29.3% of the overridden alerts were truly immune-mediated. DISCUSSION: Our recommendations would reduce interruptive alerts in half by converting them to non-interruptive alerts (46.4%). The data suggest opportunities to improve opioid-related CDS systems.
conclusionsWe evaluated overrides of opioids and used this data to suggest ways to redesign DAAs to decrease alert override rates, combat alert fatigue and improve patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.